BioWorld MedTech

Jan. 12, 2015

InVivo reopens enrollment for Neuro-Spinal Scaffold

InVivo Therapeutics (Cambridge, Massachusetts) reported the reopening of subject enrollment for the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. Read More

It's Complicated: Genome studies broaden and deepen as methods progress

FDA grants CLIA waiver for molecular diagnostic test for influenza A & B

Inside the Beltway: Palmetto's Putcha: FDA oversight of LDTs could push testing to clinics

Attached to today's issue: The MDD 4Q Report.

Financings: PureTech closes on $50 million growth stage investment round

Report from Europe; Mauna Kea reports its sales are up 10% despite 'sharply contrasting trends'

HIT Bits: Mirth to power patient health information for Arizona network

MDD's Stock Market Winners and Losers

MDD's Stock Report for the week of 1/2-1/9

Briefly noted

People in Places

Product briefs

MDD's Neurology Extra

MDD's 4Q Report: Mergers and Acquisitions: Fewer, but more valuable, deals are the trend for last quarter of 2014

4Q14 Deals Chart

MDD's 4Q Report: Financings: Series A funding and IPOs show steady resolve in 4Q14

4Q14 Financial Chart

MDD's 4Q Report: Inside the Beltway FDA publishes revised draft guidance for LDT regulation

MDD's 4Q Report: Agreements/contracts: End of year slows down a bit, but still sees quality partnerships

Today's news in brief

BioWorld

BioWorld briefs for July 20, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

Capital remains selective in ‘barbell’ biotech market

BioWorld

Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...

Elderly hands holding broken brain structure

Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability

BioWorld Science

Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...

LIT-002 is strong candidate for autism and neuropathic pain

BioWorld Science

Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...